This promotional video is funded and reviewed by Bayer for healthcare professionals only. This video is not intended for UK healthcare professionals.
The speaker did not receive compensation from Bayer for the development, recording or posting of this video. The views expressed are those of the named speaker.
EU Prescribing information for Lynkeut▼ (elinzanetant) can be found here. Please refer to local prescribing information in your country of practice before prescribing, as information and indications may vary. ▼This medicinal product is subject to additional monitoring in the EU and other countries. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Adverse event reporting information can be found at the end of this webpage.
In this short segment filmed at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany, Ludwig Kiesel explains the clinical burden of treatment‑induced vasomotor symptoms (VMS), why this issue matters to patients, and the real‑world ways these symptoms affect daily life.
He also summarises findings from a systematic review of more than 200 studies and highlights evidence showing how VMS can influence adherence among women receiving adjuvant endocrine therapy for breast cancer.1
Key points from the interview
- VMS are common in women on adjuvant endocrine therapy and are associated with poorer quality of life, including sleep disturbances, mood changes, and reduced daily functioning.
- Evidence on the economic impact is limited, but real‑world data indicate VMS can lower adherence to endocrine therapy; targeted interventions are needed to relieve these disruptive symptoms and help patients stay on their prescribed treatment.
Elinzanetant is the first dual neurokinin (NK) 1 and 3 receptor antagonist for the non-hormonal treatment of moderate-to-severe VMS associated with menopause or caused by adjuvant endocrine therapy, administered orally once daily. Latest science indicates that targeted dual blockade of NK1 and NK3 receptors in the hypothalamus and of NK1 receptors in the skin brings balance back to temperature regulation and sleep.2-5
Timestamps:
0:00 – Opening remarks
0:18 – Motivation to conduct this study
0:48 – Key findings
2:08 – Economic and healthcare system burden
2:44 – Implications for clinical practice
3:31 – Explore full poster
Speaker:
Ludwig Kiesel1
1. Professor of Gynecology and Obstetrics, Department of Gynecology and Obstetrics, University Hospital of Münster, Germany
| Adverse events should be reported. Reporting forms and information for the EU can be found here. Adverse events should also be reported to Bayer via Safe Track. |
References
- Kiesel L et al. Adjuvant endocrine therapy for hormone receptor-positive breast cancer: a systematic literature review on the burden of induced vasomotor symptoms (iVMS). Poster CN105. ESMO Congress, 17-21 October, 2025.
- European Medicines Agency (EMA). Lynkuet. 2025. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/lynkuet. Last accessed: 5 November 2025.
- Simon JA et al. Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1). Menopause. 2023;30(3):239-46.
- Pinkerton JAV et al. Elinzanetant for the treatment of vasomotor symptoms associated with menopause: OASIS 1 and 2 randomized clinical trials. JAMA. 2024;332(16):1343-54.
- Cardoso F et al. Elinzanetant for vasomotor symptoms from endocrine therapy for breast cancer. N Engl J Med. 2025;393(8):753-63.
MA-M_ELZ-ALL-0115-1
